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(B) Efficiency for siRNA-mediated knockdown of PERK, IRE1 and CHOP was assessed by immunoblotting in cell extracts from LNCaP-S14 cells transfected with the specific siRNAs and followed by treatment with SMIP004 (40 μM) for 24h. PERK knockdown was assessed based on the extent of eIF2α phosphorylation. (E) Basal NRF2 levels were visualized in LNCaP-S14 cells by immunofluorescence staining.
Staining with the secondary antibody alone was used as a specificity control. (G) LAPC4 cells were treated with increasing concentrations of SMIP004 or SMIP004-7 (0.1 µM to 40 µM) for 72 hours, and cell viability was measured by MTT assay. The graph represents the mean ± standard deviations of three replicates per point (normalized to untreated cells).
(H) LAPC4 xenografts were performed as described in Supplementary Experimental Procedures, and changes in tumor volumes (mm 3 ) (day 7 -day 0) were calculated for each animal.
(I) MDA-MB 231 xenografts were performed as described in the Supplementary Experimental
Procedures. The graph to the left represents the tumor volume ± standard deviations over time.
The graph to the right represents changes in body weights (average ± standard deviations).
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